Study of Wegovy safety during pregnancy
Part of Hormones & metabolism clinical trials.
This study looks at health outcomes for pregnant women and their babies after taking Wegovy or other weight-loss medicines. It may help understand if these medicines are safe during pregnancy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were pregnant and had a pregnancy event like a live birth, stillbirth, or miscarriage between June 2021 and February 2034.
- You were between 15 and 50 years old at the time you became pregnant.
- You took Wegovy or another weight-loss medicine (like phentermine or orlistat) around the time you got pregnant or during pregnancy.
- You had health insurance that covered medical and pharmacy benefits for at least 6 months before pregnancy and 42 days after the pregnancy ended.
- You were not taking other similar diabetes or weight-loss medicines (like Ozempic) during the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks the safety of taking Wegovy during pregnancy. Researchers want to understand potential risks and outcomes when people are exposed to Wegovy in early or any stage of pregnancy.
This study observes how Wegovy works in everyday medical practice for people who are starting it for the first time. It will help doctors learn more about its real-life benefits and safety.
This study tracks how well Wegovy (a once-weekly injection for weight loss) works for people in Korea who are just starting the medication. It helps doctors understand real-world results outside of a research clinic.
This study tests an investigational drug called survodutide to see if it helps women who are overweight or obese and going through or finished menopause lose weight. If you qualify, you may receive the study drug or a placebo, and the study will track your weight loss over time.
This study tests a weight-loss medication called semaglutide (Wegovy) combined with a hormonal intrauterine device (Mirena) for treating early-stage uterine cancer or precancerous changes in the uterus, while preserving fertility. The goal is to see if this combination can shrink or eliminate the abnormal cells, allowing patients to keep the option of having children.
This trial tests a new weekly injection called GZR18 against the existing drug Wegovy for weight loss in adults who are overweight or obese. It aims to see which is more effective and safe for helping people lose weight and improve related health conditions.
Hear when a new Pregnancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.